I suspect few managements pay great heed to message board advice while they do read.
A longtime ago, I was surprised ["horrified" may be more accurate] to learn "CHUCKEE!" [the raucous taunt of a horde of bashers for a CEO with the first name Charles] was daily driven to distraction by the name-calling.
The item of contention for the development-stage biotech was building a sales arm for a synthetic mushroom drug to treat cancer based on the jack-o-lantern mushroom.
Two advanced Phase III trials were still in the clinic. CHUCKEE had leased another cancer drug that had been approved but failed in the marketplace to use for testing and training the sales team.
Then the widely-hailed synthetic mushroom drug failed both Phase III trials for safety reasons.
I was stunned that one longtime stockholder threw every penny he could beg or borrow [he wrote that he had applied for every credit card he saw advertised and immediately borrowed every penny available for cards he was issued to buy more stock].
The astonishing secret sauce became visible in a few days after the commonplace biotech trainwreck:
The leased drug that had failed in the marketplace previously had caught fire with a vigorous sales effort by hungry hires!
CHUCKEE! became Charles again, or maybe even Chuck, and the stock became a big winner.
You can google the synthetic jack-o-lantern cancer drug [it was still in development last I looked]. Charles has passed on to the Great Beyond and I think the original biotech has splintered into parts or something but I tell you it was one great story back then.
For myself, I had sold before the trainwreck. My joy turned to tears.
Oh yeah, this is another stock set for glory or doom in short order as my totally unreliable vision sees it.
I am hoping for glory, of course, but my surmise is the safest bet is doom.
I think MZEI had to shat or get off the pot. Further stalling would only have led to a further zombie existence until some kind benevolence shoveled some dirt on the corpse.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.